Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks

Autor: Isabelle Deschamps, Stanley C. Erck, John K. Billington, Emmanuel Hanon, Julie Louise Gerberding, Sabrina Ivol, John Shiver, Julia A. Spencer, Johan Van Hoof

Publikováno v: Health Security

The COVID-19 pandemic is a stark reminder of the heavy toll that emerging infectious diseases (EIDs) with epidemic and pandemic potential can inflict. Vaccine development, scale-up, and commercialization is a long, expensive, and risky enterprise tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c9c309c9a9e6fb29cb90b1e59bedb54

Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.

Autor: Billington J; John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium., Deschamps I; Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France., Erck SC; Stanley C. Erck, MBA, is President and Chief Executive Officer, Novavax, Gaithersburg, MD., Gerberding JL; Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ., Hanon E; John Billington, JD, MPH, is Director, Science Policy, and Emmanuel Hanon, PhD, DVM, is Senior Vice President, Head of R&D; both at GSK Vaccines, Wavre, Belgium., Ivol S; Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands., Shiver JW; Isabelle Deschamps, PhD, is Head of Global Vaccine Public Affairs; and John W. Shiver, PhD, is Senior Vice President R&D; both with Sanofi Pasteur, Lyon, France., Spencer JA; Julie L. Gerberding, MD, MPH, is Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy, and Population Health; and Julia A. Spencer, PhD, is Associate Vice President, Global Public Policy; both with Merck & Co., Inc., Kenilworth, NJ., Van Hoof J; Sabrina Ivol is Senior Specialist, Policy; and Johan Van Hoof, MD, is Managing Director; both with Janssen Vaccines & Prevention BV, Janssen Pharmaceuticals R&D, Leiden, Netherlands.

Publikováno v: Health security [Health Secur] 2020 May/Jun; Vol. 18 (3), pp. 241-249. Date of Electronic Publication: 2020 Apr 29.